RS Research develops novel nanomedicines and a drug-delivery platform aimed at cancer therapies, with multiple candidates in preclinical development. The company also offers preclinical services to industrial and academic partners, including biosimilar characterization and in vivo experiment design. It intends to advance its own candidates toward investigational new drug (IND) applications. RS Research plans to use recent funding to move its drug-delivery platform from preclinical steps toward IND filings. The company was founded in March 2015 and is based in Teknopark Istanbul, Turkey. Key management includes Dr. Rana Sanyal (Chief Science Officer) and Sena Nomak (Chief Operating Officer).

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2017